Cui Xulei
10
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
2 terminated/withdrawn out of 10 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Programmed Intermittent Bolus Infusion of Thoracic Paravertebral Block for Hepatectomy
Role: lead
QLB Versus PVB for Acute Pain and Quality of Recovery After Laparoscopic Partial Nephrectomy
Role: lead
Continuous Paravertebral Block on Postoperative Quality of Recovery After Hepatectomy
Role: lead
TMQLB Versus TPVB for Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery
Role: lead
CTPVB for Hepatectomy
Role: lead
TQLB for Postoperative Pain After Laparoscopic Partial Nephrectomy
Role: lead
Continous Quadratus Lumborum Block for Hepatic Surgery With Right Subcostal Incision
Role: lead
Quadratus Lumborum Block : Effect on Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery
Role: lead
Ultrasound-guided Continuous Adductor Canal Block for Analgesia After Total Knee Replacement: Comparison of Short-axis and Long-axis Techniques
Role: lead
Thoracic Paravertebral Block : Effect on Acute Pain and Chronic Pain of Hepatectomy With Right J-shape Subcostal Incision
Role: lead
All 10 trials loaded